1
|
Calderone CE, Turner EM, Hayek OE, Summerlin D, West JT, Rais-Bahrami S, Galgano SJ. Contemporary Review of Multimodality Imaging of the Prostate Gland. Diagnostics (Basel) 2023; 13:diagnostics13111860. [PMID: 37296712 DOI: 10.3390/diagnostics13111860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 05/03/2023] [Accepted: 05/23/2023] [Indexed: 06/12/2023] Open
Abstract
Tissue changes and the enlargement of the prostate, whether benign or malignant, are among the most common groups of diseases that affect men and can have significant impacts on length and quality of life. The prevalence of benign prostatic hyperplasia (BPH) increases significantly with age and affects nearly all men as they grow older. Other than skin cancers, prostate cancer is the most common cancer among men in the United States. Imaging is an essential component in the diagnosis and management of these conditions. Multiple modalities are available for prostate imaging, including several novel imaging modalities that have changed the landscape of prostate imaging in recent years. This review will cover the data relating to commonly used standard-of-care prostate imaging modalities, advances in newer technologies, and newer standards that impact prostate gland imaging.
Collapse
Affiliation(s)
- Carli E Calderone
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Eric M Turner
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Omar E Hayek
- Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - David Summerlin
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Janelle T West
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Soroush Rais-Bahrami
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
- Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
- O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Samuel J Galgano
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
- O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| |
Collapse
|
2
|
Abstract
OBJECTIVE. The purpose of this study was to identify the sensitivity of contrast-enhanced CT in detecting high-grade prostate adenocarcinoma. MATERIALS AND METHODS. A retrospective analysis included 100 patients with prostate cancer proven by biopsy between January 2010 and December 2017 who underwent staging CT of the abdomen and pelvis within 3 months of diagnosis. The control subjects were 100 randomly selected aged-matched male outpatients with no known history of malignancy who underwent contrast-enhanced CT of the abdomen and pelvis in the same time period as the patients with cancer. Two readers, blinded to both groups, independently assessed the likelihood of prostate cancer on the basis of the CT finding of focal abnormally increased peripheral enhancement in the prostate. Binary classification of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) was used to assess the diagnostic utility of CT versus the reference standard of transrectal ultrasound-guided biopsy. RESULTS. Eighty-three of 100 patients with biopsy-proven prostate cancer and 92 of 100 control subjects were correctly identified (sensitivity, 0.83; specificity, 0.92; PPV, 0.91; NPV, 0.84). There was no significant difference in diagnostic accuracy among subjects with different Gleason scores. Interrater agreement on both the cancer and control patients was 0.76 as assessed by Cohen kappa statistic. CONCLUSION. Incidental detection of a focal area of increased enhancement in the periphery of the prostate at contrast-enhanced CT may represent a clinically significant cancer and deserves further workup with prostate-specific antigen measurement and correlation with clinical risk factors for prostate cancer.
Collapse
|
3
|
Tanahashi Y, Goshima S, Kondo H, Noda Y, Sakurai K, Kawada H, Kawai N, Furui S, Matsuo M. Additional value of venous phase added to aortic CT angiography in patients with aortic aneurysm. Clin Imaging 2017; 44:51-56. [DOI: 10.1016/j.clinimag.2017.04.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 02/01/2017] [Accepted: 04/10/2017] [Indexed: 01/16/2023]
|
4
|
Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology. Eur J Radiol 2016; 85:261-267. [DOI: 10.1016/j.ejrad.2015.10.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Revised: 10/01/2015] [Accepted: 10/16/2015] [Indexed: 11/23/2022]
|
5
|
Is primary tumor detectable in prostatic carcinoma at routine contrast-enhanced CT? Clin Imaging 2015; 39:623-6. [PMID: 25682301 DOI: 10.1016/j.clinimag.2015.01.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Revised: 12/20/2014] [Accepted: 01/12/2015] [Indexed: 11/22/2022]
Abstract
OBJECTIVES To determine if prostatic carcinoma (PCa) is detectable at routine contrast-enhanced CT (CECT). MATERIALS AND METHODS With institutional review board approval, 63 consecutive PCa patients underwent CECT before therapy. Two blinded radiologists assessed for rounded focal enhancing peripheral zone nodules. Diagnostic accuracy and inter-observer agreement were compared by Gleason Score (GS). RESULTS Overall sensitivity was 63-76% with moderate agreement, K=0.42. The false-positive rate was 15%. Sensitivities and agreement for GS 9-10, 7-8 and 6 PCa were 84-91%, 73-84%, 41-71%, (P=.023 and .001) and K=(0.72, 0.69, 0.23). CONCLUSIONS CECT has good sensitivity for detecting GS ≥7 PCa with substantial agreement and a low false-positive rate.
Collapse
|
6
|
Łuczyńska E, Heinze-Paluchowska S, Blecharz P, Jereczek-Fossa B, Petralia G, Bellomi M, Stelmach A. Correlation between CT perfusion and clinico-pathological features in prostate cancer: a prospective study. Med Sci Monit 2015; 21:153-62. [PMID: 25582437 PMCID: PMC4301468 DOI: 10.12659/msm.891401] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background The aim of the study was to assess the correlation between computed tomography perfusion (PCT) parameters and PSA levels, Gleason score, and pTNM stage in patients with prostate cancer (PCa). Material/Methods One hundred twenty-five patients with localized PCa were prospectively enrolled in the study. All patients were diagnosed due to suspicious prostate findings and elevated PSA serum levels and underwent PCT followed by core biopsy and radical prostatectomy. Blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability-surface (PS) area product were computed in the suspected PCa area and normal prostatic tissue. Core biopsy followed by prostatectomy was performed 2–4 weeks after PCT. Correlation between PCT findings and PSA levels, Gleason score, and pTNM stage were analyzed. Results The mean age of patients was 64 years. All patients had elevated PSA levels (mean value 6.2 ng/ml). Nineteen patients (15.9%) were at low risk of recurrence, 91 (76.5%) were at moderate risk, and 9 (7.6%) were at high risk according to National Comprehensive Cancer Network criteria. PCa was visible on PCT as focal peripheral CT enhancement in 119 out of 125 patients (sensitivity 95.2%). Significant correlations between BV, BF, and PS values and PSA level were found (p<0.05), as well as a trend for difference between BV, BF, and PS in poorly and moderately differentiated tumors (according to Gleason score) in comparison with highly differentiated PCa (p<0.08). The analysis also revealed a correlation between mean perfusion values and BV, MTT, PS, and pTNM cancer stage (p<0.04). Conclusions Our study suggests that in low- and intermediate- risk patients, PCT parameters correlate with PSA values, Gleason score, and pTNM stage and can be useful for initial tumor staging.
Collapse
Affiliation(s)
- Elżbieta Łuczyńska
- Department of Radiology, Center of Oncology, M. Skłodowska-Curie Memorial Institute, Cracow, Poland
| | | | - Paweł Blecharz
- Department of Gynecologic Oncology, Center of Oncology, M. Skłodowska-Curie Memorial Institute, Cracow, Poland
| | | | - Giuseppe Petralia
- Department of Radiology, European Institute of Oncology, Milan, Italy
| | - Massimo Bellomi
- Department of Radiology, European Institute of Oncology, Milan, Italy
| | - Andrzej Stelmach
- Department of Surgery, Center of Oncology, M. Skłodowska-Curie Memorial Institute, Cracow, Poland
| |
Collapse
|
7
|
Luczynska E, Blecharz P, Dyczek S, Stelmach A, Petralia G, Bellomi M, Jereczek-Fossa BA, Jakubowicz J. Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients. Ecancermedicalscience 2014; 8:476. [PMID: 25435904 PMCID: PMC4239130 DOI: 10.3332/ecancer.2014.476] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Indexed: 12/04/2022] Open
Abstract
Purpose The aim of this study is to assess the usefulness of perfusion computer tomography (pCT) in prostate cancer (PCa) diagnostics. Materials and Methods 94 patients with biopsy-proven PCa were enrolled in the study. Dynamic pCT of the prostate gland was performed for 50 seconds after an intravenous injection of contrast medium. Blood flow (BF), blood volume (BV), mean transit time (MTT) and permeability surface area product (PS) were computed in the suspected PCa area and in normal prostatic tissue. Results PCa was visible in pCT in 90 of the 94 examined patients as a focal peripheral CT enhancement. When PCa was located in the peripheral zone (PZ), it was visible on perfusion maps, mostly showing an early peak followed by wash-out. The average values of all perfusion parameters were higher for tumour than for normal prostate tissue (p < 0.000). BV and BF were dependent on tumour grade expressed by the Gleason score (GS). All PCa cases were divided into groups, according to histological grade, as low (GS ≤ 6), medium (GS = 7), and high (GS > 7). In high-grade PCa, the mean BF value was significantly higher (p = 0.001) than the mean value of BF low- and medium-grade PCa (p = 0.011). Similar results were obtained regarding the mean values of BV; the more aggressive the cancer grade, the higher the mean BV value (p = 0.04). Conclusion CT quantitative perfusion imaging allows PCa to be distinguished from normal prostate tissue. The highest values for BF and BV were observed in the most aggressive PCa grade.
Collapse
Affiliation(s)
- Elzbieta Luczynska
- Radiology Department, Centre of Oncology, M Sklodowska-Curie Memorial Institute, Cracow Branch, Cracow, Poland
| | - Pawel Blecharz
- Gynecologic Oncology Department, Centre of Oncology, M Sklodowska-Curie Memorial Institute, Cracow Branch, Cracow, Poland
| | - Sonia Dyczek
- Radiology Department, Centre of Oncology, M Sklodowska-Curie Memorial Institute, Cracow Branch, Cracow, Poland
| | - Andrzej Stelmach
- Radiotherapy Department, Centre of Oncology, M Sklodowska-Curie Memorial Institute, Cracow Branch, Cracow, Poland
| | | | - Massimo Bellomi
- Radiology Department, European Institute of Oncology, Milan, Italy ; Radiology Department, European Institute of Oncology, Milan, Italy
| | | | - Jerzy Jakubowicz
- Surgery Department, Centre of Oncology, M Sklodowska-Curie Memorial Institute, Cracow Branch, Cracow, Poland
| |
Collapse
|
8
|
Fütterer JJ, Barentsz JO, Heijmijnk STWPJ. Imaging modalities for prostate cancer. Expert Rev Anticancer Ther 2014; 9:923-37. [DOI: 10.1586/era.09.63] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
9
|
Zhang XF, Lu Q, Wu LM, Zou AH, Hua XL, Xu JR. Quantitative iodine-based material decomposition images with spectral CT imaging for differentiating prostatic carcinoma from benign prostatic hyperplasia. Acad Radiol 2013; 20:947-56. [PMID: 23830601 DOI: 10.1016/j.acra.2013.02.011] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2012] [Revised: 02/18/2013] [Accepted: 02/18/2013] [Indexed: 02/08/2023]
Abstract
RATIONALE AND OBJECTIVES To investigate the value of iodine-based material decomposition images produced via spectral computed tomography (CT) in differentiating prostate cancer (PCa) from benign prostate hyperplasia (BPH). MATERIALS AND METHODS Fifty-six male patients underwent CT examination with spectral imaging during arterial phase (AP), venous phase (VP), and parenchymal phase (PP) of enhancement. Iodine concentrations of lesions were measured and normalized to that of the obturator internus muscle. Lesion CT values at 75 keV (corresponding to the energy of polychromatic images at 120 kVp) were measured and also normalized; their differences between AP and VP, VP and PP, and PP and AP were also obtained. The two-sample t-test was performed for comparisons. A receiver operating characteristic curve was generated to establish the threshold for normalized iodine concentration (NIC). RESULTS Fifty-two peripheral lesions were found, which were confirmed by biopsy as 28 cases of PCa and 24 BPHs. The NICs of prostate cancers significantly differed from those of the BPHs: 2.38 ± 1.72 compared with 1.21 ± 0.72 in AP, respectively, and 2.67 ± 0.61 compared with 2.27 ± 0.77 in VP. Receiver operating characteristic analysis indicated that an NIC of 1.24 in the AP provided a sensitivity of 88% and a specificity of 71% for differentiating PCa from BPH. CONCLUSIONS Spectral CT imaging enabled quantitative depiction of contrast medium uptake in prostatic lesions and improved sensitivity and specificity for differentiating PCa from BPH.
Collapse
|
10
|
|
11
|
Heijmink SWTPJ, Fütterer JJ, Strum SS, Oyen WJG, Frauscher F, Witjes JA, Barentsz JO. State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer. Acta Oncol 2011; 50 Suppl 1:25-38. [PMID: 21604938 DOI: 10.3109/0284186x.2010.578369] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In the diagnostic process of prostate cancer, several radiologic imaging modalities significantly contribute to the detection and localization of the disease. These range from transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) to positron emission tomography (PET). Within this review, after evaluation of the literature, we will discuss the advantages and disadvantages of these imaging modalities in clarifying the patient's clinical status as to whether he has prostate cancer or not and if so, where it is located, so that therapy appropriate to the patient's disease may be administered. TRUS, specifically with the usage of intravenous contrast agents, provides an excellent way of directing biopsy towards suspicious areas within the prostate in the general (screening) population. MRI using functional imaging techniques allows for highly accurate detection and localization, particularly in patients with prior negative ultrasound guided biopsies. A promising new development is the performance of biopsy within the magnetic resonance scanner. Subsequently, a proposal for optimal use of radiologic imaging is presented and compared with the European and American urological guidelines on prostate cancer.
Collapse
Affiliation(s)
- Stijn W T P J Heijmink
- Department of Radiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
12
|
Li MM, Rybalov M, Haider MA, de Jong IJ. Does computed tomography or positron emission tomography/computed tomography contribute to detection of small focal cancers in the prostate? J Endourol 2010; 24:693-700. [PMID: 20367444 DOI: 10.1089/end.2009.0470] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Prostate cancer is considered to be a multifocal tumor in the majority of patients. Based on histologic data after prostatectomy, there is a growing insight that a considerable number of men who receive a diagnosis in the contemporary setting of prostate-specific antigen screening have unilateral or unifocal disease. With this, the current concept of whole-gland therapy has come into discussion. The need for improvement of intraprostatic tumor characterization is clear. Molecular imaging is one of the areas of research on this aspect. The clinical indications for positron emission tomography (PET)/CT have increased rapidly in the field of oncology and are largely based on fluorodeoxyglucose (FDG) PET. Both conventional CT and FDG PET, however, cannot detect prostate cancer foci <5 mm within the prostate. Dynamic contrast-enhanced CT involves imaging a region of interest rapidly (usually <10 seconds between images) during a bolus intravenous injection of a contrast agent. Through analysis of the contrast enhancement time curves, it is possible to distinguish tissues with different microvascular properties such as cancer. The technologic aspects of both imaging techniques and the clinical results of 11C-choline PET/CT for intraprostatic tumor characterization are discussed. Based on preliminary studies, dynamic contrast-enhanced (DCE)-CT may be a useful tool for localization of prostate tumors and, perhaps more importantly, quantification of therapeutic response in prostate cancer. Validation work is necessary, however, to define its accuracy and role in therapeutic paradigms such as focal therapies, particularly given the current accuracy of MRI. In the future, combining DCE-CT with CT or (11)C-choline PET/CT may be an alternative to MRI, offering a combination of quantitative parameters that may correlate to tumor prognosis as well as cancer localization for focal therapy.
Collapse
Affiliation(s)
- Michael M Li
- Joint Department of Medical Imaging, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
13
|
Aguettaz P, Ben Cheikh A, Girouin N, Mège-Lechevallier F, Pricaz E, Lyonnet D, Rouvière O. [Portal venous phase CT of the abdomen and pelvis: do not forget the prostate!]. ACTA ACUST UNITED AC 2009; 90:836-8. [PMID: 19752790 DOI: 10.1016/s0221-0363(09)73216-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Computed tomography imaging in patients with prostate cancer. Prostate Cancer 2008. [DOI: 10.1017/cbo9780511551994.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
15
|
Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol 2007; 63:351-60. [PMID: 17709223 DOI: 10.1016/j.ejrad.2007.06.024] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2007] [Revised: 06/19/2007] [Accepted: 06/20/2007] [Indexed: 01/20/2023]
Abstract
PURPOSE To summarize current technical and biochemical aspects and clinical applications of proton magnetic resonance spectroscopy (MRS) of the human prostate in vivo. MATERIAL AND METHODS Pertinent radiological and biochemical literature was searched and retrieved via electronic media (medline, pubmed. Basic concepts of MRS of the prostate and its clinical applications were extracted. RESULTS Clinical MRS is usually based on point resolved spectroscopy (PRESS) or spin echo (SE) sequences, along with outer volume suppression of signals from outside of the prostate. MRS of the prostate detects indicator lines of citrate, choline, and creatine. While healthy prostate tissue demonstrates high levels of citrate and low levels of choline that marks cell wall turnover, prostate cancer utilizes citrate for energy metabolism and shows high levels of choline. The ratio of (choline+creatine)/citrate distinguishes between healthy tissue and prostate cancer. Particularly when combined with magnetic resonance (MR) imaging, three-dimensional MRS imaging (3D-CSI, or 3D-MRSI) detects and localizes prostate cancer in the entire prostate with high sensitivity and specificity. Combined MR imaging and 3D-MRSI exceed the sensitivity and specificity of sextant biopsy of the prostate. When MRS and MR imaging agree on prostate cancer presence, the positive predictive value is about 80-90%. Distinction between healthy tissue and prostate cancer principally is maintained after various therapeutic treatments, including hormone ablation therapy, radiation therapy, and cryotherapy of the prostate. CONCLUSIONS Since it is non-invasive, reliable, radiation-free, and essentially repeatable, combined MR imaging and 3D-MRSI of the prostate lends itself to the planning of biopsy and therapy, and to post-therapeutic follow-up. For broad clinical acceptance, it will be necessary to facilitate MRS examinations and their evaluation and make MRS available to a wider range of institutions.
Collapse
Affiliation(s)
- Ullrich G Mueller-Lisse
- Dept. of Clinical Radiology, Klinikum der Universitaet Muenchen, Standorte Grosshadern und Innenstadt, Ziemssenstrasse 1, D-80336 Muenchen, Germany.
| | | |
Collapse
|
16
|
Moradi M, Mousavi P, Abolmaesumi P. Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. ULTRASOUND IN MEDICINE & BIOLOGY 2007; 33:1010-28. [PMID: 17482752 DOI: 10.1016/j.ultrasmedbio.2007.01.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2006] [Revised: 12/28/2006] [Accepted: 01/14/2007] [Indexed: 05/15/2023]
Abstract
This paper reviews the state of the art in computer-aided diagnosis of prostate cancer and focuses, in particular, on ultrasound-based techniques for detection of cancer in prostate tissue. The current standard procedure for diagnosis of prostate cancer, i.e., ultrasound-guided biopsy followed by histopathological analysis of tissue samples, is invasive and produces a high rate of false negatives resulting in the need for repeated trials. It is against these backdrops that the search for new methods to diagnose prostate cancer continues. Image-based approaches (such as MRI, ultrasound and elastography) represent a major research trend for diagnosis of prostate cancer. Due to the integration of ultrasound imaging in the current clinical procedure for detection of prostate cancer, we specifically provide a more detailed review of methodologies that use ultrasound RF-spectrum parameters, B-scan texture features and Doppler measures for prostate tissue characterization. We present current and future directions of research aimed at computer-aided detection of prostate cancer and conclude that ultrasound is likely to play an important role in the field.
Collapse
Affiliation(s)
- Mehdi Moradi
- School of Computing, Queen's University, Kingston, Ontario, Canada
| | | | | |
Collapse
|
17
|
Prando A, Kurhanewicz J, Borges AP, Oliveira EM, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236:903-10. [PMID: 16118169 DOI: 10.1148/radiol.2363040615] [Citation(s) in RCA: 130] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
PURPOSE To prospectively evaluate the accuracy of transrectal ultrasonography (US)-guided biopsy directed with magnetic resonance (MR) spectroscopic imaging in patients with an elevated prostate specific antigen (PSA) level and negative findings at prior biopsy by using subsequent biopsy results as the reference standard. MATERIALS AND METHODS The committee on human research approved this study, and written informed consent was obtained. MR imaging and MR spectroscopic imaging were performed in 42 men (age range, 45-75 years; average age, 63.3 years; median age, 65 years) with negative findings at two or more prostatic biopsies and at digital rectal examination. MR spectroscopic data were rated on a scale of 1 (benign) to 5 (malignant) on the basis of standardized metabolic criteria. Abnormal voxels were overlaid on the corresponding transverse transrectal US images and used to perform voxel-guided biopsy of the prostate. All patients subsequently received an extended-pattern biopsy scheme. RESULTS Thirty-one of 42 patients demonstrated metabolic abnormalities that were suspicious for cancer (voxels with scores > or = 4). Eleven patients with negative MR spectroscopic imaging results also had negative biopsy findings. Cancer was detected in 17 (55%) of 31 men with positive MR spectroscopic imaging findings (voxels with scores > or = 4) with a sensitivity of 100%, specificity of 44%, positive predictive value of 55%, negative predictive value of 100%, and accuracy of 67%. In men with at least one spectroscopic voxel with a score of 5 (12 of 17 men), the sensitivity, specificity, positive and negative predictive values, and accuracy were 71%, 84%, 75%, 81%, and 79%, respectively. CONCLUSION Metabolic data from MR spectroscopic imaging can be transferred to transrectal US images and used to sample regions of cancer in men with rising PSA levels and negative findings at prior biopsy with good accuracy.
Collapse
Affiliation(s)
- Adilson Prando
- Department of Radiology, Vera Cruz Hospital, Av Andrade Neves 707, Campinas SP, 13013-161, Brazil.
| | | | | | | | | |
Collapse
|
18
|
Ives EP, Burke MA, Edmonds PR, Gomella LG, Halpern EJ. Quantitative Computed Tomography Perfusion of Prostate Cancer: Correlation with Whole-Mount Pathology. ACTA ACUST UNITED AC 2005; 4:109-12. [PMID: 16197611 DOI: 10.3816/cgc.2005.n.018] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE Microvessel density within the prostate is associated with presence of cancer, disease stage, and disease-specific survival. We evaluated multidetector computed tomography (CT) to estimate prostate perfusion and localize prostate cancer. PATIENTS AND METHODS Ten subjects were evaluated with contrast enhanced CT before radical prostatectomy with the Mx8000IDT 16-slice scanner. Following baseline pelvic scan, 100 cc of Optiray 300 was administered intravenously (4 cc per second). Repeated dynamic scans through the prostate were obtained at 20, 30, 40, 50, and 60 seconds following initiation of contrast injection. Computed tomography perfusion was compared with pathologic findings of Gleason score and tumor volume on whole-mount prostatectomy specimens. RESULTS Conventional adenocarcinoma (Gleason score, 6-10) was present in all subjects, including one who also demonstrated a mucinous variant of prostate cancer. Visible focal CT enhancement was noted in 1 patient with a high-volume tumor and a Gleason score of 10. A positive correlation between local estimates of CT perfusion and percent of prostate volume occupied by tumor in each sextant was found for half of the subjects (Pearson correlation coefficient, 0.3-0.95; mean, 0.48) but statistically significant correlation (P < 0.05; Pearson coefficient, 0.9-0.95) was present in only the 2 subjects with the highest Gleason scores (8 and 10) and the highest tumor volume (> or = 50% in > or = 1 sextant region). CONCLUSION Visible enhancement of prostate cancer during dynamic CT is present in a minority of subjects. Correlation between quantitative CT perfusion and tumor location is statistically significant only in subjects with localized high-volume, poorly differentiated prostate cancer.
Collapse
Affiliation(s)
- Elizabeth P Ives
- Department of Radiation/Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | | | | | | | | |
Collapse
|
19
|
Meirelles LR, Billis A, Cotta ACS, Nakamura RT, Caserta NMG, Prando A. Prostatic atrophy: evidence for a possible role of local ischemia in its pathogenesis. Int Urol Nephrol 2004; 34:345-50. [PMID: 12899225 DOI: 10.1023/a:1024405920019] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Prostatic atrophy may be histologically and at ultrasound similar to adenocarcinoma causing diagnostic confusion, its frequency increases with age but the etiopathogenesis is unknown. Based on a systematic study in autopsies previously done by one of us, ischemia due to local intense arteriosclerosis seems to be a potential factor for its pathogenesis. Absent blood flow in areas of prostatic atrophy might be a further evidence for a possible role of ischemia. From a total of 298 patients biopsied and studied by gray-scale and color Doppler transrectal ultrasound in the period 1998 to 2001, 33 patients had suspicious lesions (37 hypoechoic nodules and 3 heterogeneous lesions) showing prostatic atrophy as the only diagnosis on all these biopsied lesions. Adenocarcinoma, high-grade intraepithelial neoplasia or other atypical lesions were absent in all patients. On color Doppler the suspicious areas showed absent flow in 24/40 (60%), present flow in 12/40 (30%), and increased flow in 4/40 (10%) of the lesions. Absent flow in the majority of the lesions studied may be a further evidence for a possible role of local ischemia in the etiopathogenesis of prostatic atrophy.
Collapse
Affiliation(s)
- Luciana R Meirelles
- Department of Anatomic Pathology, School of Medicine, State University of Campinas (UNICAMP), Campinas, Brazil
| | | | | | | | | | | |
Collapse
|
20
|
Engelbrecht MR, Huisman HJ, Laheij RJF, Jager GJ, van Leenders GJLH, Hulsbergen-Van De Kaa CA, de la Rosette JJMCH, Blickman JG, Barentsz JO. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229:248-54. [PMID: 12944607 DOI: 10.1148/radiol.2291020200] [Citation(s) in RCA: 318] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
PURPOSE To evaluate which parameters of dynamic magnetic resonance (MR) imaging and T2 relaxation rate would result in optimal discrimination of prostatic carcinoma from normal peripheral zone (PZ) and central gland (CG) tissues and to correlate these parameters with tumor stage, Gleason score, patient age, and tumor markers. MATERIALS AND METHODS Of 58 patients with prostatic carcinoma, 36 were included for analysis. Patients underwent MR imaging at 1.5 T with an endorectal-pelvic phased-array coil and subsequently underwent prostatectomy. A T2-weighted turbo spin-echo sequence, an intermediate-weighted sequence, and a fast T1-weighted gradient-echo sequence (seven sections in 2.03 seconds) during bolus injection of 0.1 mmol gadopentetate dimeglumine per kilogram of body weight were performed. Contrast agent concentration-time curves were obtained for prostatic carcinoma and normal PZ and CG tissue by using whole-mount sections to guide placement of regions of interest. Onset time, time to peak, peak enhancement, relative peak enhancement, washout, and T2 relaxation rates were calculated. Multivariate receiver operating characteristic analysis was performed with and without relative peak enhancement. RESULTS Results of multivariate receiver operating characteristic analysis showed that relative peak enhancement demonstrated the highest area under the receiver operating characteristic curve (AUC) in the PZ and the CG (AUC = 0.93, 0.82). Results of multivariate analysis without relative peak enhancement showed that relative peak enhancement in the PZ and washout in the CG demonstrated the highest AUC (AUC = 0.9, 0.81). Pearson correlation coefficients between the dynamic parameters or T2 relaxation rates in carcinoma and the tumor stage, Gleason score, patient age, and tumor markers ranged between 0.02 and 0.44. CONCLUSION The optimal parameter for discrimination of prostatic carcinoma in the PZ and CG was relative peak enhancement. If relative peak enhancement was not used, then peak enhancement was optimal in the PZ, and washout was optimal in the CG. Poor-to-moderate correlation was present between the dynamic parameters or T2 relaxation rate in carcinoma and the tumor stage, Gleason score, patient age, tumor volume, and prostate-specific antigen.
Collapse
Affiliation(s)
- Marc R Engelbrecht
- Department of Radiology, University Medical Center Nijmegen, PO Box 9101, NL 6500 HB Nijmegen, the Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Kökeny GP, Cerri GG, Cerri LMDO, Barros ND. Adenocarcinoma da próstata: a alteração hipoecogênica difusa da próstata é um achado ultra-sonográfico importante? Radiol Bras 2001. [DOI: 10.1590/s0100-39842001000400007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Avaliar se há associação entre a observação de alteração hipoecogênica difusa da próstata, com perda da demarcação entre a zona periférica e a glândula interna, e o diagnóstico de adenocarcinoma de próstata na biópsia prostática transretal. MATERIAIS E MÉTODOS: Avaliamos 143 homens com nível sérico de antígeno prostático específico maior do que 4 ng/ml. Todos os pacientes foram submetidos à ultra-sonografia endorretal e biópsia randomizada da próstata. RESULTADOS: Foi diagnosticado adenocarcinoma de próstata em 36,4% dos pacientes. A alteração hipoecogênica difusa da próstata, caracterizada por perda da demarcação entre a zona periférica e a glândula central, foi observada em 22 pacientes e correspondeu ao diagnóstico de adenocarcinoma de próstata em 21 deles (95,4%). CONCLUSÃO: A alteração hipoecogênica difusa da próstata constituiu um critério de suspeita ultra-sonográfica de adenocarcinoma de próstata altamente significativo, já que em 95,4% das próstatas que apresentavam essas características a biópsia foi positiva para adenocarcinoma de próstata
Collapse
|
22
|
Abstract
In the Karnell Cancer Center Grand Rounds, we present a patient who underwent radical prostatectomy with bilateral pelvic lymphadenectomy, but had positive margins and subsequently developed local recurrence and then systemic disease. Pathologic and radiologic aspects of his disease are discussed. Therapeutic options at different stages of the disease are examined from the point of view of the urologist, radiation oncologist, and medical oncologist. The surgical portion of the discussion focuses on the selection of initial therapy. Both the selection of surgical candidates and choice of pre- or post-operative therapy in patients can be aided by prognostic tools looking at several variables, including prostate-specific antigen (PSA) level, Gleason score of the tumor, seminal vesicle invasion, extracapsular invasion, and lymph node involvement. Low-risk patients can be treated with monotherapy, such as radical prostatectomy, external beam radiation therapy, prostate brachytherapy, or cryosurgical ablation of the prostate. Higher risk patients may require adjuvant and possibly neoadjuvant therapy in addition. The radiation portion of the discussion focuses on the use of radiation therapy as salvage for relapsing disease. Of particular importance is the point that treating high-risk patients whose PSA levels have started to rise but are less than 1 ng/ml results in a long-term PSA control rate as high as 75%, but that limiting the use of salvage radiation therapy to patients with high PSA levels or biopsy confirmation of local recurrence in the face of a negative bone scan results in biochemical long-term control of less than 40%. In the medical oncology part of the discussion, the major focus is on the use of chemotherapy to treat patients whose disease has become resistant to hormonal therapy. Mitoxantrone plus a corticosteroid has been found to offer significant palliation for such patients. Combination therapy with estramustine plus taxanes, other microtubule inhibitors, or other agents such as topoisomerase II inhibitors, has been found to cause shrinkage of measurable soft tissue disease and diminution of serum PSA levels. The development of effective hormonal and chemotherapeutic drugs for treatment of metastatic disease has led to new interest in adjuvant and neoadjuvant therapy of high-risk patients.
Collapse
Affiliation(s)
- M J Haut
- Pennsylvania Hospital, Karnell Cancer Center, 230 West Washington Square, Philadelphia, PA 19106, USA.
| | | | | | | | | |
Collapse
|